[go: up one dir, main page]

ES8800041A1 - Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales - Google Patents

Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales

Info

Publication number
ES8800041A1
ES8800041A1 ES552794A ES552794A ES8800041A1 ES 8800041 A1 ES8800041 A1 ES 8800041A1 ES 552794 A ES552794 A ES 552794A ES 552794 A ES552794 A ES 552794A ES 8800041 A1 ES8800041 A1 ES 8800041A1
Authority
ES
Spain
Prior art keywords
gastrointestinal tract
water
active substance
substance
granules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES552794A
Other languages
English (en)
Other versions
ES552794A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12739832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8800041(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of ES552794A0 publication Critical patent/ES552794A0/es
Publication of ES8800041A1 publication Critical patent/ES8800041A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO DE PREPARACION DE COMPOSICIONES FARMACEUTICAS DE LIBERACION CONTROLADA DE UNIDADES INDIVIDUALES. CONSISTE EN MEZCLAR UNA SUSTANCIA FISIOLOGICAMENTE ACTIVA EN CANTIDAD INFERIOR AL 10 POR CIEN CON AL MENOS 50 POR CIEN DE UNA SUSTANCIA FORMADORA DE UNIDADES, TAL COMO CELULOSA CRISTALINA A UNA TEMPERATURA COMPRENDIDA ENTRE 5GC Y 50GC; AÑADIR A LA MEZCLA FORMADA 0-30 POR CIEN DE UN AGENTE CONTROLADOR DE LA LIBERACION Y MEZCLAR A LA MISMA TEMPERATURA; Y GRANULAR LA MEZCLA RESULTANTE A UNA TEMPERATURA COMPRENDIDA ENTRE 5GC Y 40GC.
ES552794A 1985-03-08 1986-03-07 Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales Expired ES8800041A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4618085 1985-03-08

Publications (2)

Publication Number Publication Date
ES552794A0 ES552794A0 (es) 1987-10-16
ES8800041A1 true ES8800041A1 (es) 1987-10-16

Family

ID=12739832

Family Applications (1)

Application Number Title Priority Date Filing Date
ES552794A Expired ES8800041A1 (es) 1985-03-08 1986-03-07 Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales

Country Status (8)

Country Link
US (1) US4772475A (es)
EP (2) EP0533297B1 (es)
JP (1) JPH0772129B2 (es)
KR (1) KR930007245B1 (es)
CA (1) CA1264293A (es)
DE (2) DE3650657D1 (es)
ES (1) ES8800041A1 (es)
ZA (1) ZA861565B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690487A (en) * 1983-11-14 1987-09-01 Allied Corporation Hermetically sealed fiber optic connector
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
US5028433A (en) * 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
IE64061B1 (en) * 1989-09-04 1995-07-12 Yamanouchi Pharma Co Ltd External preparation containing amusulosin
CA2034171A1 (en) * 1990-01-22 1991-07-23 Gorm Wagner Method of treating erectile dysfunction
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
WO1991019483A1 (en) * 1990-06-20 1991-12-26 Advanced Polymer Systems, Inc. Compositions and methods for the controlled release of soluble active substances
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6602861B1 (en) * 1992-04-16 2003-08-05 Research Corporation Technologies, Inc. Acylated phospholipid drugs
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9505032D0 (en) * 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
SE9702338D0 (sv) * 1997-06-18 1997-06-18 Astra Ab An analytical method and industrial process including the same
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7255876B2 (en) * 2001-07-27 2007-08-14 Astellas Pharma, Inc. Composition comprises sustained-release fine particles and manufacturing method thereof
DE20220415U1 (de) * 2001-11-07 2003-10-09 Synthon Bv Tamsulosin-Tabletten
ES2287474T3 (es) * 2002-04-24 2007-12-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Combinacion farmaceutica para el tratamiento de la hiperplasia prostatica benigna o para la prevencion a la largo plazo de la retencion urinaria aguda.
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
KR100592512B1 (ko) * 2002-11-22 2006-07-03 서울약품공업(주) 탐술로신 또는 약제학적으로 허용되는 이의 염을활성성분으로 하는 서방성 배뇨장애 치료제
CA2515585A1 (en) * 2003-01-27 2004-08-12 Yoji Tanijiri Enteric sustained-release fine particles for tamsulosin or its salt and manufacturing method thereof
US20040253309A1 (en) * 2003-01-27 2004-12-16 Yamanouchi Pharmaceutical Co., Ltd. Enteric sustained-release fine particles of tamsulosin and its salt and manufacturing method thereof
AU2004263054B2 (en) * 2003-08-12 2009-11-26 Kyungdong Pharm. Co., Ltd. Preparing method for controlled released type tablet tamsulosin HCl and the tablet thereof
JP2005104914A (ja) * 2003-09-30 2005-04-21 Kyowa Yakuhin Kogyo Kk 塩基性薬剤含有製剤
KR100436701B1 (ko) * 2003-11-07 2004-06-22 주식회사 씨티씨바이오 염산 탐스로신 함유 방출 조절형 제제 및 그의 제조방법
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR100582350B1 (ko) * 2004-02-17 2006-05-22 한미약품 주식회사 탐수로신 염산염의 경구투여용 조성물 및 이의 서방성과립 제제
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
KR100681660B1 (ko) 2004-03-17 2007-02-09 주식회사종근당 방출제어 펠릿의 약제학적 조성물
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
EP1618873B1 (de) * 2004-07-14 2007-06-06 Siegfried Generics International AG Granulat zur kontrollierten Freisetzung von Tamsulosin, enthaltend Alginat
US7238839B2 (en) * 2004-10-07 2007-07-03 Divi's Laboratories Limited Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
JP2008523143A (ja) * 2004-12-13 2008-07-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 月経困難症の治療のためのα−アドレナリン遮断剤の使用
JP2008525313A (ja) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
JP2006232696A (ja) * 2005-02-23 2006-09-07 Taisho Pharm Ind Ltd 徐放性製剤
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
EP2026766A1 (en) * 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US20080113030A1 (en) * 2006-11-09 2008-05-15 Ching-Fen Hsiao Sustained release tamsulosin formulations
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
PT2222300E (pt) 2007-12-13 2014-07-28 Vanda Pharmaceuticals Inc Método e composição para tratamento de uma condição mediada por recetores da serotonina
ES2527515T3 (es) * 2007-12-13 2015-01-26 Vanda Pharmaceuticals Inc. Método y composición para tratar una afección mediada por un adrenoceptor alfa
WO2009112874A1 (en) * 2008-03-10 2009-09-17 Eurodrug Laboratories B.V. Modified release composition comprising doxofylline
US8529953B2 (en) * 2008-07-01 2013-09-10 Sawai Pharmaceutical Co., Ltd. Process for production of spherical microparticles comprising tamsulosin hydrochloride
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
WO2013045352A1 (de) 2011-09-30 2013-04-04 Basf Se Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
DE112014002521T5 (de) * 2013-05-21 2016-06-02 Ngk Insulators, Ltd. Verfahren zur Herstellung einer piezoelektrischen Vorrichtung, piezoelektrische Vorrichtung, und piezoelektrisches, selbststützendes Substrat
WO2014203137A2 (en) 2013-06-21 2014-12-24 Wockhardt Limited Pharmaceutical compositions of tamsulosin or salts thereof
BR102013020508B1 (pt) 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CZ2015225A3 (cs) 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
KR101879133B1 (ko) 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
KR101957694B1 (ko) 2018-05-28 2019-03-13 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
JP7370124B2 (ja) * 2018-11-09 2023-10-27 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
JP7370125B2 (ja) * 2018-11-09 2023-10-27 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB630439A (en) * 1945-09-11 1949-10-13 Ethan Allan Brown Improvements in or relating to pharmaceutical preparations
DE1467781A1 (de) * 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe
DE1962016C3 (de) * 1969-12-11 1979-11-08 Uzina De Medicamente Bucuresti, Bukarest Verfahren zur Herstellung von Tabletten mit protrahierter Wirkung
CA952431A (en) * 1970-09-28 1974-08-06 Frank M. Bardani Controlled release medicament
FR2183546B1 (es) * 1972-05-10 1975-06-20 Servier Lab
JPS50131867A (es) * 1974-04-08 1975-10-18
US4495189A (en) * 1975-11-27 1985-01-22 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Condensed pyrimidines
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
JPS535112A (en) * 1976-03-08 1978-01-18 Santen Pharmaceutical Co Ltd New cysteine derivatives
JPS5332111A (en) * 1976-09-07 1978-03-27 Asahi Chem Ind Co Ltd Composition for tablet
DD137186A1 (de) * 1978-06-30 1979-08-22 Guenther Magister Verfahren zur herstellung von rieselfaehigen produkten aus zellulosepulver
JPS6011888B2 (ja) * 1978-10-11 1985-03-28 参天製薬株式会社 リウマチ疾患治療薬
JPS55153715A (en) * 1979-05-18 1980-11-29 Nikken Kagaku Kk Prolonged granule of theophylline
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
JPS6056122B2 (ja) * 1980-05-21 1985-12-09 塩野義製薬株式会社 徐放性製剤
JPS574921A (en) * 1980-06-13 1982-01-11 Chugai Pharmaceut Co Ltd Remedy for cardiovascular disorder
US4469704A (en) * 1980-12-26 1984-09-04 Ss Pharmaceutical Co., Ltd. 2,3-Butanediol diester derivatives, process for producing the same, and an antiulcer drug containing the same
JPS58189114A (ja) * 1982-04-30 1983-11-04 Ss Pharmaceut Co Ltd 抗潰瘍剤
US4552765A (en) * 1982-05-14 1985-11-12 Santen Pharmaceutical Co., Ltd. Aletheine derivatives
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
JPS59190913A (ja) * 1983-04-14 1984-10-29 Eisai Co Ltd ケノデオキシコ−ル酸含有顆粒剤
JPS6036410A (ja) * 1983-08-08 1985-02-25 Unitika Ltd 生分解性薬物供与体の製造方法
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.

Also Published As

Publication number Publication date
EP0194838A2 (en) 1986-09-17
ES552794A0 (es) 1987-10-16
JPS629A (ja) 1987-01-06
EP0533297A1 (en) 1993-03-24
DE3688532D1 (de) 1993-07-15
CA1264293A (en) 1990-01-09
EP0194838A3 (en) 1988-02-03
KR930007245B1 (ko) 1993-08-04
DE3688532T2 (de) 1993-09-23
KR860006984A (ko) 1986-10-06
US4772475A (en) 1988-09-20
EP0194838B1 (en) 1993-06-09
EP0533297B1 (en) 1997-11-19
JPH0772129B2 (ja) 1995-08-02
ZA861565B (en) 1986-10-29
DE3650657D1 (de) 1998-01-02

Similar Documents

Publication Publication Date Title
ES8800041A1 (es) Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales
US5387420A (en) Morphine-containing efferverscent composition
SU1443788A3 (ru) Способ получени твердой лекарственной формы
EP0228164B1 (en) Effervescent composition containing ibuprofen
IL104865A (en) Pulsatile once-a-day delivery systems for minocycline and process for their preparation
DE69331906D1 (de) Granulierte pharmazeutische zusammensetzung
ES8602407A1 (es) Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado
FI870588A0 (fi) Menetelmä hitaasti vapauttavan kiinteän annostusmuodon valmistamiseksi
WO1995001782A3 (en) Method for making freeze dried drug dosage forms
HU900638D0 (en) Process for preparing modified gembifrozil preparations with retard release
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
US5322698A (en) Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
CS247190B2 (en) Method of agent with porous matrix production on polycaprolactam base
EP0159735A1 (en) Pharmaceutical composition containing tetracyclin or doxycyclin salts and a process of preparing such a composition
HUT34345A (en) Process for producing tablets with controlled dissolution of active ingredients independent of ph
EP0293975B1 (en) Dry, rapidly soluble, compositions of beta-lactam antibiotics
CA2384301A1 (en) Sustained-release drug formulations for implantation
IE44733B1 (en) Theophylline compositions
PT98774A (pt) Processo para a preparacao de composicoes melhoradas de acido 5-(2,5-dimetilfenoxi)-2,2-dimetilpentanoico (gemfibrozil)
SU1369128A1 (ru) Способ приготовления антисептических препаратов на основе пентахлорфенолята натрия

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20070825